FIELD: medicine, pharmaceutics.
SUBSTANCE: there is offered application of cyclosporine for preparing a pharmaceutical composition for prevention or treatment of hepatitis C related infections or HCV induced disorders, where cyclosporine (a) is bound with human recombinant cyclophilin with a bound constant (BC) is at least 0.7, where the BC represents a decimal logarithm of the relation of IC50 cyclosporine and IC50 cyclosporine A in simultaneous experiment for estimating by competitive assay ELISA; and (b) exhibits activity in a lymphocyte reaction in a mixed culture 5% and less in comparison with the activity of cyclosporine A, where cyclosporine is [MeIle]cyclosporine or a compound of formula 
(versions).
EFFECT: prepared compounds inhibit HCV and in treatment do not suppress immune system, can be used in combination with other anti-HCV agents.
12 cl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF MODIFIED CYCLOSPORINES | 2007 |
|
RU2463071C2 |
| CYCLOSPORINE | 1991 |
|
RU2085589C1 |
| NONIMMUNOSUPPRESSIVE CYCLOSPORINE FOR TREATING CONGENITAL ULLRICH MYOPATHY | 2008 |
|
RU2462262C2 |
| METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTION | 2006 |
|
RU2440822C2 |
| NOVEL CYCLOSPORIN DERIVATIVES FOR TREATMENT AND PREVENTION OF VIRAL INFECTIONS | 2011 |
|
RU2601742C2 |
| CYCLOSPORIN DERIVATIVES, SUBSTITUTED WITH 3-ETHER AND 3-THIOETHER FOR TREATING AND PREVENTING INFECTIOUS HEPATITIS C | 2005 |
|
RU2399628C2 |
| APPLICATION OF SANGLIFERIN FOR TREATING HEPATITIS C VIRUS | 2006 |
|
RU2427372C2 |
| MODIFIED CYCLOSPORIN THAT CAN BE USED AS PRODRUG AND ITS USING | 2002 |
|
RU2290196C2 |
| USING TYPE III PEGYLATED INTERFERONS FOR TREATING HEPATITIS C | 2009 |
|
RU2496514C2 |
| PREVENTIVE OR THERAPEUTIC AGENT AGAINST VIRAL DISEASE | 2007 |
|
RU2433827C2 |
